Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avalyn PharmaAVLN -1.01%11 Quick Ratio is 10.19 as of Dec. 2025, which is 12% below its 10-year median of 11.64. GuruFocus rates AVLN with a GF Score™ of 11/100. Among 1,411 Biotechnology companies, Avalyn Pharma ranks better than 79.16% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Avalyn Pharma's quick ratio for the quarter that ended in Dec. 2025 was 10.19.
Avalyn Pharma has a quick ratio of 10.19. It generally indicates good short-term financial strength.
The historical rank and industry rank for Avalyn Pharma's Quick Ratio or its related term are showing as below:
AVLN'
s Quick Ratio Range Over the Past 10 Years
Min: 10.19 Med: 11.64 Max: 13.08
Current: 10.19
During the past 2 years, Avalyn Pharma's highest Quick Ratio was 13.08. The lowest was 10.19. And the median was 11.64.
AVLN's Quick Ratio is ranked better than 79.16% of 1411
companies
in the Biotechnology industry
Industry Median: 3.56
vs AVLN: 10.19
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Avalyn Pharma Quick Ratio Related Terms
Avalyn Pharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for Avalyn Pharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma Quick Ratio Chart
Avalyn Pharma Annual Data
Trend
Dec24
Dec25
Quick Ratio
13.08
10.19
Avalyn Pharma Semi-Annual Data
Dec24
Dec25
Quick Ratio
13.08
10.19
AVLN vs TRAX, IMTX, ARDX: Quick Ratio Comparison
For the Biotechnology subindustry, Avalyn Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalyn Pharma Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalyn Pharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Avalyn Pharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Avalyn Pharma's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma (AVLN) has a Quick Ratio of 10.19 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Avalyn Pharma and its competitors. This is 12% below median its historical median of 11.64. Over the past decade, Avalyn Pharma's Quick Ratio has ranged from 10.19 to 13.08. According to the industry distribution chart, Avalyn Pharma ranks #294 out of 1411 companies in the Biotechnology industry, placing it in the top 20.8%.
Is Avalyn Pharma's Quick Ratio too high?
Avalyn Pharma's current Quick Ratio of 10.19 is 12% below median its 10-year median of 11.64. Over the past 10 years, this metric has ranged from a low of 10.19 to a high of 13.08. The Biotechnology industry median Quick Ratio is 3.56. Avalyn Pharma's value of 10.19 is 186.2% above this industry median. Based on the distribution chart, Avalyn Pharma ranks #294 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avalyn Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's Quick Ratio compare to TRAX and IMTX?
According to the Biotechnology industry distribution chart, Avalyn Pharma ranks #294 out of 1411 companies for Quick Ratio. This places Avalyn Pharma in the top 21% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.56. Avalyn Pharma's value of 10.19 is 186.2% above this benchmark. Historically, Avalyn Pharma's own Quick Ratio has ranged from 10.19 to 13.08 over the past decade. While the company's 10-year median is 11.64 vs. the industry median of 3.56, Avalyn Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.56, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avalyn Pharma's current Quick Ratio of 10.19 is 186.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Avalyn Pharma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalyn Pharma's current Quick Ratio is 10.19, which is 12% below median its own 10-year median of 11.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current Quick Ratio of 10.19. The current Quick Ratio is 10.19, which is 12% below median its 10-year median of 11.64 and 186.2% above the Biotechnology industry median of 3.56. Avalyn Pharma's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current Quick Ratio is 10.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score
Get the complete analysis for AVLN
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVLN has been successfully added to your 
